…
Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company offers precision laser systems and imaging systems for biology markets. It also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services. In addition, the company manufactures and distributes medical products for reproductive medicine; manufactures bespoke workstations, incubators, and equipment for IVF laboratories; researches, designs, develops, sells, installs, and services in-vitro diagnostic systems; and manufactures ovum pickup needles, catheters, and other devices. Further, the company offers Cell-Tek Microscope Chamber, a product for controlling temperature, air flow, humidification, and air quality; laminar flow workstations, incubators, and related products; and artificial intelligence enabled CASA software, consumables, and image analysis systems for the ART and laboratory markets, as well as capital equipment and consumables, software, and other services. It sells its products and services under Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, MICROPTIC, Gynétics, and Embryotech brand names through a direct sales force in the United States, Germany, France, Australia, Denmark, Belgium, Spain, and the United Kingdom, as well as through distributors to fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 100 countries. Hamilton Thorne Ltd. is headquartered in Beverly, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -1.50M | 2.60M | 5.34M | 2.10M | 2.41M |
| Net income | -0.82M | 1.91M | 2.43M | 1.30M | 1.05M |
| Selling general administrative | 14.95M | 10.82M | 8.56M | 6.72M | 5.17M |
| Selling and marketing expenses | 14.76M | 12.30M | 10.41M | 8.11M | 7.63M |
| Gross profit | 41.31M | 34.86M | 30.26M | 24.86M | 23.09M |
| Ebit | 0.38M | 17.06M | 15.51M | 3.83M | 5.22M |
| Ebitda | 7.47M | 21.94M | 19.60M | 7.50M | 8.19M |
| Depreciation and amortization | 7.10M | 4.88M | 4.08M | 3.67M | 2.97M |
| Operating income | 0.38M | 17.06M | 15.51M | 3.83M | 5.22M |
| Other operating expenses | 90.36M | 58.68M | 50.12M | 49.53M | 41.69M |
| Interest expense | 1.37M | 0.43M | 0.36M | 0.69M | - |
| Tax provision | - | 0.09M | 1.82M | 0.59M | - |
| Interest income | - | 0.29M | 0.33M | 1.29M | - |
| Income tax expense | -0.68M | 0.12M | 2.29M | 0.80M | 1.36M |
| Total revenue | 90.73M | 75.74M | 65.64M | 53.35M | 46.92M |
| Total operating expenses | 40.93M | 17.80M | 14.75M | 21.03M | 17.86M |
| Cost of revenue | 49.42M | 40.88M | 35.38M | 28.50M | 23.83M |
| Total other income expense net | -1.87M | -14.46M | -10.17M | -1.73M | -2.81M |
| Net income applicable to common shares | - | 1.91M | 2.43M | 0.97M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 146.01M | 86.67M | 75.06M | 69.81M | 76.27M |
| Intangible assets | 30.29M | 20.30M | 19.29M | 17.09M | 13.73M |
| Other current assets | 2.82M | - | - | - | 0.86M |
| Total liab | 60.76M | 30.45M | 19.11M | 18.74M | 26.03M |
| Total stockholder equity | 85.25M | 56.22M | 55.96M | 51.07M | 50.24M |
| Other current liab | 0.00M | - | - | - | 1.26M |
| Common stock | 97.60M | 66.56M | 65.32M | 62.85M | 69.60M |
| Retained earnings | -22.82M | -16.70M | -18.61M | -21.04M | -28.55M |
| Good will | 39.02M | 18.89M | 14.77M | 11.71M | 14.00M |
| Other assets | - | 3.95M | 3.17M | 3.91M | - |
| Cash | 12.84M | - | - | - | 16.59M |
| Cash and equivalents | - | 16.67M | 17.93M | 21.83M | - |
| Total current liabilities | 22.46M | 13.60M | 10.47M | 11.73M | 15.76M |
| Current deferred revenue | 0.33M | - | - | - | 0.52M |
| Net debt | 24.02M | - | - | - | -1.24M |
| Short term debt | 7.77M | 0.00M | 0.00M | 0.00M | 7.05M |
| Short long term debt total | 36.86M | - | - | - | 15.36M |
| Other stockholder equity | 12.21M | -3.04M | 1.01M | 2.25M | 7.84M |
| Property plant equipment | - | 5.84M | 4.30M | 3.28M | - |
| Total current assets | 45.72M | 37.35M | 33.52M | 33.81M | 30.32M |
| Net receivables | 11.02M | 7.04M | 5.19M | 3.99M | 4.06M |
| Long term debt | - | 11.13M | 4.40M | 4.20M | - |
| Inventory | 19.04M | 12.27M | 9.53M | 7.40M | 8.80M |
| Accounts payable | 14.35M | - | - | - | 6.93M |
| Accumulated other comprehensive income | -1.74M | - | - | - | 1.35M |
| Non currrent assets other | 19.83M | - | - | - | 0.15M |
| Non current assets total | 100.29M | - | - | - | 45.95M |
| Long term debt total | - | 13.77M | 6.51M | 5.84M | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total cashflows from investing activities | - | -10.28M | -9.08M | -1.66M | - |
| Total cash from financing activities | 8.53M | 9.40M | -0.53M | 6.37M | 0.52M |
| Net income | -0.82M | 2.49M | 3.05M | 1.30M | 1.05M |
| Change in cash | -9.76M | -0.05M | -5.16M | 11.22M | -2.08M |
| Begin period cash flow | 22.59M | 22.64M | 27.81M | 16.59M | 18.67M |
| End period cash flow | 12.84M | 22.59M | 22.64M | 27.81M | 16.59M |
| Total cash from operating activities | 5.38M | 2.34M | 7.03M | 7.97M | 8.46M |
| Depreciation | 7.10M | 4.88M | 4.08M | 3.67M | 2.97M |
| Other cashflows from investing activities | - | -7.43M | -6.85M | 0.00M | - |
| Change to inventory | -1.08M | -2.59M | -1.19M | -0.82M | -2.29M |
| Change to account receivables | -0.39M | -2.45M | -0.18M | -1.15M | 1.05M |
| Sale purchase of stock | - | 0.38M | 0.57M | 5.12M | - |
| Other cashflows from financing activities | 2.82M | 1.98M | 0.57M | 1.50M | 0.70M |
| Capital expenditures | 5.03M | 3.70M | 2.80M | 2.22M | 1.88M |
| Change in working capital | -2.13M | -4.45M | -3.47M | -0.11M | 0.83M |
| Stock based compensation | 1.61M | 2.02M | 1.79M | 1.03M | 0.95M |
| Other non cash items | 16.25M | 13.77M | 13.24M | 10.70M | 7.34M |
| Free cash flow | 0.35M | -1.36M | 4.23M | 5.74M | 6.59M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HTL Hamilton Thorne Ltd. |
- -% |
2.24 | - | 45.87 | 4.73 | 3.92 | 3.64 | 42.65 |
| PRN Profound Medical Corp |
-0.12 1.23% |
9.65 | - | - | 21.06 | 3.72 | 11.94 | -7.93 |
Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company offers precision laser systems and imaging systems for biology markets. It also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services. In addition, the company manufactures and distributes medical products for reproductive medicine; manufactures bespoke workstations, incubators, and equipment for IVF laboratories; researches, designs, develops, sells, installs, and services in-vitro diagnostic systems; and manufactures ovum pickup needles, catheters, and other devices. Further, the company offers Cell-Tek Microscope Chamber, a product for controlling temperature, air flow, humidification, and air quality; laminar flow workstations, incubators, and related products; and artificial intelligence enabled CASA software, consumables, and image analysis systems for the ART and laboratory markets, as well as capital equipment and consumables, software, and other services. It sells its products and services under Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, MICROPTIC, Gynétics, and Embryotech brand names through a direct sales force in the United States, Germany, France, Australia, Denmark, Belgium, Spain, and the United Kingdom, as well as through distributors to fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 100 countries. Hamilton Thorne Ltd. is headquartered in Beverly, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. David B. Wolf | Executive Chairman | NA |
| Mr. Francesco Fragasso CPA | Chief Financial Officer | NA |
| Mr. Justin Jaundoo | Vice President of Corporate Development | NA |
| Mr. Brett M. Fulton | Senior VP & GM of HT Inc. | NA |
| Dr. Julia Heinzmann | Managing Director of Gynemed, GmbH & Co KG | NA |
| Dr. Ekaterina Torchilin MBA, Ph.D. | President, CEO & Director | NA |
| Mr. Thomas Kenny | Senior Vice President Global Operations & Sustaining Engineering and Management Rep | NA |
| Ms. Kimberly Marolda | Director of HR | NA |
| Mr. Eric V. Dorman | President of Embryotech Laboratories Inc | NA |
| Dr. Fabian Sell | Chief Executive Officer of Gynemed | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.